Eikon Therapeutics Inc
EIKN
Company Profile
Business description
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Contact
230 Harriet Tubman Way
MillbraeCA94030
USAT: +1 341 777-0566
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
384
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 53,939.74 | 409.38 | -0.75% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,349.00 | 14.44 | -0.05% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,711.96 | 11.59 | -0.15% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |